ANDA 75128, held by Watson Labs Teva. Nifedipine.
As of Nov 16, 2026, ANDA 75128 (Afeditab Cr), held by Watson Labs Teva, was first approved by FDA on Mar 10, 2000, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 10, 2000 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Afeditab Cr30MG ยท tablet, extended release;oral | Nifedipine | Discontinued |
| May 3, 2005 | Supplement 11Labeling | Approved | None posted |
| Dec 30, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Jul 17, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Jul 17, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Jan 17, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Jul 23, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Mar 10, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters